Patrys (ASX:PAB) Preferred Dividends : A$0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Patrys Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Patrys's preferred dividends for the six months ended in Dec. 2024 was A$0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.00 Mil.

Patrys Preferred Dividends Historical Data

The historical data trend for Patrys's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Patrys Preferred Dividends Chart

Patrys Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Preferred Dividends

Get a 7-Day Free Trial

Patrys Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Preferred Dividends	Get a 7-Day Free Trial															-	-	-	-	-

Patrys Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Patrys (ASX:PAB) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Patrys Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Patrys Ltd (ASX:PAB) » Definitions » Preferred Dividends

Comparable Companies

Traded in Other Exchanges

N/A

Address

Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205

Website

https://www.patrys.com

Patrys Ltd focuses on the development of natural human antibody-based therapies for the treatment of cancer. The company's product includes Deoxymab 3E10, PAT-SC1, PAT-DX1 PAT-DX1-NP, PAT-DX3, and PAT-LM1. Its main technology is Deoxymab 3E10, a DNA damage repair (DDR) antibody that penetrates live cell nuclei and inhibits key mechanisms of DNA repair in target cancer cells.